HGH Fragment 176-191 vs 5-Amino-1MQ
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Frag 176-191, HGH Frag
The lipolytic fragment of human growth hormone. Contains the fat-burning portion of HGH without effects on blood sugar or cell proliferation.
Also: 5-amino-1-methylquinolinium, NNMT Inhibitor
A selective NNMT (nicotinamide N-methyltransferase) inhibitor that enhances cellular energy metabolism. Not a peptide but a small molecule research compound commonly used alongside peptides for fat loss and metabolic support.
Key Comparison Insights
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- HGH Fragment 176-191 has stronger research evidence (Human Trials) compared to 5-Amino-1MQ (Animal Studies).
Detailed Comparison
| Attribute | HGH Fragment 176-191 | 5-Amino-1MQ |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Fragment 176-191 mimics the way natural HGH regulates fat metabolism but without adverse effects on blood sugar or growth. It stimulates lipolysis and inhibits lipogenesis, specifically targeting adipose tissue. | 5-Amino-1MQ inhibits NNMT, an enzyme that regulates NAD+ and SAM (S-adenosyl methionine) levels. By blocking NNMT, it increases NAD+ availability, enhancing mitochondrial function, promoting fat oxidation, and supporting cellular energy metabolism. It does not affect appetite or food intake. |
| Common Dosing | 250-500 mcg daily 1-2x daily, fasted | 50-75 mg daily Once daily, morning |
| Administration | Subcutaneous injection on empty stomach | Subcutaneous injection or oral |
| Typical Duration | 8-12 weeks | 4-6 weeks (cycling recommended) |
| Best Time to Take | Before bed or morning (fasted) | Morning, fasted |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Studies show enhanced fat loss, particularly in abdominal area. Research demonstrates no impact on glucose metabolism or IGF-1 levels. Works synergistically with diet and exercise for body composition improvement. | Mouse studies showed over 30% decrease in adipocyte size and 40% decrease in adipocyte volume. Treated mice had 30% lower total cholesterol. No significant impact on food intake or adverse effects observed. Human clinical data remains limited. |
Frequently Asked Questions: HGH Fragment 176-191 vs 5-Amino-1MQ
What is the difference between HGH Fragment 176-191 and 5-Amino-1MQ?
HGH Fragment 176-191 is a weight loss peptide that the lipolytic fragment of human growth hormone. contains the fat-burning portion of hgh without effects on blood sugar or cell proliferation. 5-Amino-1MQ is a weight loss peptide that a selective nnmt (nicotinamide n-methyltransferase) inhibitor that enhances cellular energy metabolism. not a peptide but a small molecule research compound commonly used alongside peptides for fat loss and metabolic support. The main differences lie in their mechanisms of action and clinical applications.
Which is better, HGH Fragment 176-191 or 5-Amino-1MQ?
Neither is universally "better" - the choice depends on your specific goals. HGH Fragment 176-191 is typically used for weight loss purposes, while 5-Amino-1MQ is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can HGH Fragment 176-191 and 5-Amino-1MQ be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using HGH Fragment 176-191 and 5-Amino-1MQ together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of HGH Fragment 176-191 and 5-Amino-1MQ is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.